Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1783-1788

  Damia, G ^a   Guidi, G ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alkylating agents; Nucleotide excision repair

Indexed keywords

ALKYLATING AGENT; CISPLATIN; MELPHALAN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, NORTHERN; CISPLATIN; COLONIC NEOPLASMS; DNA REPAIR; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA; MELPHALAN; NEOPLASMS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032189513     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00190-7     Document Type: Article

References (51)

1. 1. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54, 4313-4320.
2. 2. List AF. Preclinical investigations of drug resistance. Curr Opin Oncol 1995, 7, 19-27.
3. 3. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
4. 4. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997, 89, 1845-1853.
5. 5. Kaufmann WK, Paules RS. DNA damage and cell cycle check-points. FASEB J 1996, 10, 238-247.
6. 6. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996, 88, 1346-1360.
7. 7. Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20, 435-439.
8. 8. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990, 50, 6119-6129.
9. 9. Walker MC, Masters JR, Margison GP. O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer 1992, 66, 840-843.
10. 10. Hoeijmakers JHJ. Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer 1994, 30A, 1912-1921.
11. 11. Sancar A. DNA excision repair. Ann Rev Biochem 1996, 65, 43-81.
12. 12. Wood RD. DNA repair in eukaryotes. Ann Rev Biochem 1996, 65, 135-167.
13. 13. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996, 271, 8285-8294.
14. 14. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993, 14, 2177-2180.
15. 15. Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res 1993, 53, 3237-3240.
16. 16. Matsuda T, Saijo M, Kuraoka I, et al. DNA repair protein XPA binds replication protein A (RPA). J Biol Chem 1995, 270, 4152-4157.
17. 17. Dabholkar M, Vionnet J, Bostick Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94, 703-708.
18. 18. Bramson J, McQuillan A, Panasci LC. DNA repair enzyme expression in chronic lymphocytic leukemia vis-a-vis nitrogen mustard drug resistance. Cancer Lett 1995, 90, 139-148.
19. 19. Dabholkar MD, Berger MS, Vionnet JA, et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995, 55, 1261-1266.
20. 20. Chen ZP, Malapetsa A, Marcantonio D, Mohr G, Brien S, Panasci LC. Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Res 1996, 56, 2475-2478.
21. 21. Yen L, Woo A, Christopoulopoulos G, et al. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Mutat Res 1995, 337, 179-189.
22. 22. Codegoni AM, Broggini M, Pitelli M, Torri W, Mangini C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997, 65, 130-137.
23. 23. Damia G, Imperatori L, Citti L, Mariani L, D'Incalci M. 3-methyladenine-DNA-glycosylase and O6-alkylguanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br J Cancer 1996, 73, 861-865.
24. 24. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979, 18, 5294-5299.
25. 25. Fan S, Smith ML, Rivet II DJ, et al. Disruption of p53 sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55, 1649-1654.
26. 26. Herbomel P, Bourachot B, Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell 1984, 39, 653-662.
27. 27. Sijbers AM, Laat WL de, Ariza RR, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996, 86, 811-822.
28. 28. Li L, Lu X, Peterson CA, Legerski RJ. An interaction between the DNA repair factor XPA and replication protein A appears essential for nucleotide excision repair. Mol Cell Biol 1995, 15, 5396-5402.
29. 29. Park CH, Bessho T, Matsunaga T, Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 1995, 270, 22657-22660.
30. 30. Matsunaga T, Mu D, Park CH, Reardon JT, Sancar A. Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995, 270, 20862-20869.
31. 31. Nagai A, Saijo M, Kuraoka I, et al. Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein. Biochem Biophys Res Commun 1995, 211, 960-966.
32. 32. He Z, Henricksen LA, Wold MS, Ingles CJ. RPA involvement in the damage-recognition and incision steps of nucleotide excision repair. Nature 1995, 374, 566-569.
33. 33. Li L, Peterson CA, Lu X, Legerski RJ. Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair. Mol Cell Biol 1995, 15, 1993-1998.
34. 34. Spek PJ van der, Eker A, Rademakers S, et al. XPC and human homologs of RAD23: intracellular localization and relationship to other nucleotide excision repair complexes. Nucleic Acids Res 1996, 24, 2551-2559.
35. 35. Dabholkar M, Bostick Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992, 84, 1512-1517.
36. 36. Geleziunas R, McQuillan A, Malapetsa A, et al. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 1991, 83, 557-564.
37. 37. Friedberg EC. Relationships between DNA repair and transcription. Ann Rev Biochem 1996, 65, 15-42.
38. 38. Bhatia PK, Wang Z, Friedberg EC. DNA repair and transcription. Current Opin Genet Develop 1996, 6, 146-150.
39. 39. Hoeijmakers JH, Egly JM, Vermeulen W. TFIIH: a key component in multiple DNA transactions. Current Opin Genet Develop 1996, 6, 26-33.
40. 40. Peterson J, Yen L, Alpert L, et al. Expression of the DNA nucleotide excision repair gene ERCC1 in lung cancer cells. Relationship to acquired and intrinsic resistance to cisplatin. Proc Ann Meet Am Assoc Cancer Res 1995, 36, 357 (Abstract).
41. 41. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996, 66, 779-783.
42. 42. Tsuzuki T, Sakumi K, Shiraishi A, et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 1996, 17, 1215-1220.
43. 43. Engelward BP, Dreslin A, Christensen J, Huszar D, Kurahara C, Samson L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J 1996, 15, 945-952.
44. 44. Vilpo JA, Vilpo LM, Szymkowski DE, O'Donovan A, Wood RD. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol Cell Biol 1995, 15, 290-297.
45. 45. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996, 271, 19645-19648.
46. 46. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997, 3, 1763-1767.
47. 47. Branch P, Hampson R, Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 1995, 55, 2304-2309.
48. 48. Hangaishi A, Ogawa S, Mitani K, et al. Mutations and loss of expression of a mismatch repair gene, hMLH1, in leukemia and lymphoma cell lines. Blood 1997, 89, 1740-1747.
49. 49. Colella G, Vikhanskaya F, Codegoni AM, Bonazzi C, D'Incalci M, Broggini M. hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis 1998, 19, 691-694.
50. 50. Zeng Rong N, Paterson J, Alpert L, Tsao MS, Viallet J, Alaoui Jamali MA. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995, 55, 4760-4764.
51. 51. Moorehead RA, Armstrong SG, Rainbow AJ, Singh G. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*). Cancer Chemother Pharmacol 1996, 38, 245-253.